The DOI matches its Crossref record; 235 of the 235 references it cites were found in a registry or an index.
Immune Therapy for Cancer
Abstract
Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-established cancer therapies. Immune modulation is a principal element of supportive care for many high-dose chemotherapy regimens. In addition, immune activation is now appreciated as central to the therapeutic mechanism of bone marrow transplantation for hematologic malignancies. Advances in our understanding of the molecular interactions between tumors and the immune system have led to many novel investigational therapies and continue to inform efforts for devising more potent therapeutics. Novel approaches to immune-based cancer treatment strive to augment antitumor immune responses by expanding tumor-reactive T cells, providing exogenous immune-activating stimuli, and antagonizing regulatory pathways that induce immune tolerance. The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–235 of 235
CpG DNA activation and plasma-cell differentiation of CD27− naive human B cells
Huggins, J., Pellegrin, T., Felgar, R. E., Wei, C., Brown, M., Zheng, B., MILNER, E. C. B., Bernstein, S. H., Sanz, I., & Zand, M. S. (2006) · Blood · doi:10.1182/blood-2006-03-008441 · Cited by 162
Imiquimod for Actinic Keratosis: Systematic Review and Meta-Analysis
Hadley, G., Derry, S., & Moore, R. A. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700264 · Cited by 162
Brichard, V. G., & Lejeune, D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.038 · Cited by 160
Atanackovic, D., Altorki, N. K., Cao, Y., Ritter, E., Ferrara, C. A., Ritter, G., Hoffman, E. W., Bokemeyer, C., Old, L. J., & Gnjatic, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707140104 · Cited by 158
Hofmann, M. A., Kors, C., Audring, H., Walden, P., Sterry, W., & Trefzer, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4df · Cited by 153
Higuchi, T., Iwama∥, T., Yoshinaga, K., Toyooka, M., Taketo, M. M., & Sugihara, K. (2003) · PubMed · Cited by 151
Zhang, Q., Yang, X. J., Pins, M., Javonovic, B., Kuzel, T. M., Kim, S., Parijs, L. V., Greenberg, N. M., Liu, V., Guo, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3169 · Cited by 149
Ogden, C. A., Pound, J. D., Batth, B. K., Owens, S., Johannessen, I., Wood, K., & Gregory, C. D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.3015 · Cited by 147
Targeting of Antigens to Activated Dendritic Cells In vivo Cures Metastatic Melanoma in Mice
Mahnke, K., Qian, Y., Fondel, S., Brueck, J., Becker, C., & Enk, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0938 · Cited by 145
Topp, M. S., Riddell, S. R., Akatsuka, Y., Jensen, M. C., Blattman, J. N., & Greenberg, P. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021288 · Cited by 144
Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer
Simons, J. W., Carducci, M. A., Mikhak, B., Lim, M. K., Biedrzycki, B. A., Borellini, F., Clift, S., Hege, K. M., Ando, D. G., Piantadosi, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0145 · Cited by 134
Michael, A., Ball, G., Quatan, N., Wushishi, F., Russell, N., Whelan, J., Chakraborty, P., Leader, D., Whelan, M., & Pandha, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2337 · Cited by 125
Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers
Kondo, T., Kono, H., Miyamoto, N., Yoshida, R., Toki, H., Matsumoto, I., Hara, M., Inoue, H., Inatsuki, A., Funatsu, T., et al. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430618 · Cited by 118
The immunoregulatory role of CD1d-restricted natural killer T cells in disease
van der Vliet, H. J., Molling, J. W., Blomberg, B. M. E. V., Nishi, N., Kölgen, W., van den Eertwegh, A. J. M., Pinedo, H. M., Giaccone, G., & Scheper, R. J. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.03.003 · Cited by 117
The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer
Lynch, D. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00621.x · Cited by 112
Vambutas, A., DeVoti, J. A., Nouri, M., Drijfhout, J. W., Lipford, G. B., Bonagura, V. R., van der Burg, S. H., & Melief, C. J. M. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.049 · Cited by 110
Chang, A. E., Li, Q., Jiang, G., Sayre, D. M., Braun, T., & Redman, B. G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.023 · Cited by 109
Leonard, J. P., Link, B. K., Emmanouilides, C. E., Gregory, S. A., Weisdorf, D. J., Andrey, J., Hainsworth, J. D., Sparano, J. A., Tsai, D. E., Horning, S. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0815 · Cited by 108
Finn, O. J., & Forni, G. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00317-5 · Cited by 107
Eslick, G. D. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i19.2991 · Cited by 98
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 91
Self-citationMarcus, R. E., & Hagenbeek, A. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00789.x · Cited by 91
Induction of Tumor Immunity Following Allogeneic Stem Cell Transplantation
Wu, C. J., & Ritz, J. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90004-2 · Cited by 83
Targeting TRAIL Agonistic Receptors for Cancer Therapy
Carlo‐Stella, C., Lavazza, C., Locatelli, A., Viganò, L., Gianni, A. M., & Gianni, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2774 · Cited by 77
Appropriate Use of Cervical Cancer Vaccine
Zimet, G. D., Shew, M. L., & Kahn, J. A. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.092806.131644 · Cited by 71
Immunity to Melanoma Antigens: From Self‐Tolerance to Immunotherapy
Slingluff, C. L., Chianese‐Bullock, K. A., Bullock, T. N. J., Grosh, W. W., Mullins, D. W., Nichols, L. A., Olson, W. C., Petroni, G. R., Smolkin, M. E., & Engelhard, V. H. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90007-8 · Cited by 65
Nonsteroidal anti‐inflammatory drugs and risk of lung cancer
Hernández–Dı́az, S., & Rodríguez, L. A. G. (2007) · International Journal of Cancer · doi:10.1002/ijc.22514 · Cited by 56
Enhancing cancer vaccines with immunomodulators
Berinstein, N. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.043 · Cited by 56
Capitalizing on the Immunogenicity of Dying Tumor Cells
Fonseca, C., & Dranoff, G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2245 · Cited by 56
Self-citationLans, T. E., Grünhagen, D. J., de Wilt, J. H. W., van Geel, A. N., & Eggermont, A. M. M. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.093 · Cited by 54
Dendritic cell fusion vaccines for cancer immunotherapy
Rosenblatt, J. M., Kufe, D. W., & Avigan, D. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.5.703 · Cited by 53
Experience with hepatitis A and B vaccines
Davis, J. P. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.07.011 · Cited by 49
Cancer vaccines for established cancer: how to make them better?
Andrews, D. M., Maraskovsky, E., & Smyth, M. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00612.x · Cited by 47
Iinuma, T., Homma, S., Noda, T., Kufe, D. W., Ohno, T., & Toda, G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci17323 · Cited by 45
Kim, Y. H., Girardi, M., McAuley, S., & Schmalbach, T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.6600 · Cited by 23
Cited by
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Self-citation
Metadata
- Authors
- Dougan, M., & Dranoff, G.
- Venue
- Annual Review of Immunology
- Publisher
- Annual Reviews
- Published
- 2009-04-01
- Volume
- 27
- Issue
- 1
- Pages
- 83-117
- ISSN
- 0732-0582 (ISSN-L)
- 1545-3278
- OpenAlex
- W2156222101
- Cited by
- 607
- References
- 235
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.